Real-World Achievement of Skin Clearance Targets and Improved Quality of Life With Risankizumab in Psoriasis Patients With Moderate Skin Involvement (BSA ≥ 3–10%). SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 6, p. s421, 2024. DOI: 10.25251/skin.8.supp.421. Disponível em: https://skin.dermsquared.com/skin/article/view/3087. Acesso em: 3 jul. 2025.